Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.
Paradigm 2 evaluated N9-GP, a long-acting FIX...(read more
Novo Nordisk A/S (NVO) and Emisphere Technologies, Inc. (EMIS) recently announced that they have modified their agreement for the development and commercialization of oral...(read more
In the last couple of weeks or so I've had posts about understanding the role luck plays in portfolio management and the importance of managing position sizes in the portfolio. Both of...(read more